Showing 2642 results
- Media Release /In pivotal study, everolimus reduced risk of disease progression by 52%; showed 11.0-month median progression-free survival vs 3.9 months for placebo[1] Advanced, progressive, nonfunctional…
- Media Release /Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) biosimilar offers US patients reduced injection volume in citrate-free formulationAs one of the only adalimumab HCF biosimilars…
- Key Release /Ad hoc announcement pursuant to Art. 53 LR U.S. District Court for the District of Delaware ruled the Entresto (sacubitril / valsartan) ‘combination patent’ to be invalid Novartis will appeal…
- Biography /
- Media Library /
- Featured News /
Novartis announced the company’s financial results for the second quarter and first half of 2023.
- Media Release /DTx Pharma is a preclinical stage biotechnology company that focuses on developing siRNA therapies for neuroscience indications, leveraging its proprietary fatty acid ligand-conjugated…
Pagination
- ‹ Previous page
- 1
- …
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- …
- 265
- › Next page